Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It ‘Disappointing’
On Tuesday, Ikena Oncology Inc (NASDAQ:IKNA) discontinued the clinical IK-930 program, the company’s TEAD1- selective Hippo pathway inhibitor, and continued clinical development of IK-595, a novel MEK-RAF molecular glue.
Concurrently, Ikena is evaluating strategic options for the company and its development pipeline.
The company said that based on a review of clinical data to date, available resources, and strategic priorities, the company decided to discontinue the development of IK-930.
The IK-930 Phase 1 program will begin winding down activities; treatment will continue for enrolled patients who have derived benefits.
The company will seek strategic options for the program, including potential partners for developing IK-930 in combination with other targeted agents.
In November 2023, Ikena shared initial data from twenty-six patients treated in …
Full story available on Benzinga.com
